Updated: May 7
Discovered in 1969, cannabidivarin, or CBDV, is the varin version of CBD. It has been found to deliver a range of medicinal benefits, including potential anticonvulsant and neurological benefits and the ability to relieve nausea.
A 2019 study entitled "Effects of Cannabidivarin (CBDV) on Brain Excitation and Inhibition Systems in Adults With and Without Autism Spectrum Disorder (ASD)" that was published in the journal Translational Psychiatry explored the potential benefits of the use of CBDV in the treatment of autism.
The human trial study, which involved 34 adults, noted that "no effective pharmacological treatments for the core symptoms of autism" currently exist. Thus, phytocannabinoids from hemp such as CBDV are important based on their potential role in treatment of autism and related neurological disorders.
The study noted the subjective efficacy experienced by participants in the study. "Individual variation in response depended on baseline biochemistry," reported the study's authors.
The study concluded, "We have demonstrated that a single acute dose of CBDV 'shifts' subcortical levels of Glx, the brain's primary excitatory neurotransmitter, in the living adult human brain."
A 2019 study entitled "Cannabidivarin Completely Rescues Cognitive Deficits and Delays Neurological and Motor Defects" that was published in the Journal of Psychopharmacology investigated the ability of CBDV to be "beneficial toward neurological and social deficits." The preclinical study, conducted on rodent subjects, concluded that "CBDV administration exerts an enduring rescue of memory deficit."
A 2019 study entitled "Effects of Non-Euphoric Plant Cannabinoids on Muscle Quality and Performance" that was published in the British Journal of Pharmacology explored the ability of CBDV to treat muscular dystrophy and employed rodent test subjects.
Copyright © 2021 Higher Learning LV™
The preclinical research examined the use of three cannabinoids in the treatment of muscular dystrophy and overall improvements in muscle control: CBD, CBDV, and THCV. The study found that CBDV, in a dosage of 60 mg/kg, "prevented the loss of locomotor activity, reduced inflammation, and restored autophagy" (the ability of the body to clean out damaged or dead cells).
To learn more, subscribe to the Higher Learning LV™ Knowledgebase, the largest ad-free cannabis article/video repository in the world!